All KEYTRUDA articles
-
NewsStudy reveals how bacteria in microbiome medicine trigger tumor-killing cells
Microbiotica has presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.